The cyclooctadepsipeptide
PF1022A and the aminophenylamidines
amidantel, deacylated
amidantel (dAMD) and
tribendimidine were tested as examples for
drug classes potentially interesting for development as
anthelmintics against human
helminthiases. These compounds and
levamisole were tested alone and in combination to determine their efficacy against the rat hookworm Nippostrongylus brasiliensis. After three oral treatments, intestinal worms were counted.
Drug effects on parasite morphology were studied using scanning electron microscopy (SEM). Plasma pharmacokinetics were determined for
tribendimidine and dAMD. All drugs reduced worm burden in a dose-dependent manner, however
amidantel was significantly less active than the other aminophenylamidines. Combinations of
tribendimidine and dAMD with
levamisole or
PF1022A at suboptimal doses revealed additive effects. While
PF1022A caused virtually no changes in morphology,
levamisole, dAMD and
tribendimidine caused severe contraction, particularly in the hind body region. Worms exposed to combinations of
PF1022A and aminophenylamidines were indistinguishable from worms exposed only to aminophenylamidines. After oral treatment with
tribendimidine, only the active metabolite dAMD was detectable in plasma and concentrations were not significantly different for oral treatment with dAMD. The results support further evaluation of cyclooctadepsipeptides alone and in combination with
cholinergic drugs to improve efficacy. Combining these with registered drugs may help to prevent development of resistance.